In addition, yesterday's edition of US-PharmaTechnologist.com included an article on the appointment of Dr Frank Deane as the new president of manufacturing operations at Eli Lilly .
He was promoted within the company from the role of vice president of quality, which he had held since 2001.
Click here to see full article.
CellCyte Genetics has appointed Mark Reys as vice president of operations, where he will oversee CellCyte's daily operations including sourcing and manufacturing.
Reys moves from Precor where he was leading a creative team focussing on innovative strategies to outsource development and production abilities.
Prior to that he was a general manger for IRC North America, a Japan-based chemical and rubber producer.
"My Reys brings to CellCyte Genetics a wide array of skills and experience in areas such as business model development, product development, project management as well as foreign and domestic sourcing.
His expertise within the manufacturing environment will bolster the team as we move forward with our newly-established device division," CellCyte executive vice president and chief scientific officer Dr Ron Berninger said.
Meanwhile, Whatman , a global supplier of separations technology to the life sciences industry, has appointed Chris Rickard as finance director.
He replaces Phil Greenhalgh, who is leaving the company to pursue other interests.
In the new role, Rickard will also take responsibility for IT, supply chain management and facilities management.
He joins Whatman from VT Group, a FTSE 250 company, where he was finance director.
Whatman chief executive Kieran Murphy said: "Chris Rickard brings a wealth of experience to Whatman, having been the finance director of a number of sizable listed companies.
He also has enormous operational experience which will serve us well during a time of restructuring at Whatman as we seek to improve our customer service, product quality and overall group performance."
In addition, Whatman also announced the resignation of Ian Bonnar as chief operating officer.
His responsibilities for manufacturing will transfer to Manfred Baumann.
Nektar Therapeutics has undergone some organisational changes to put in place a new structure which aims to solidify its leadership position in the development of PEGylated, which involves attaching Polyethylene Glycol (PEG) to molecules, and pulmonary technology- based therapeutics.
As a result, Dr Hoyoung Huh has been promoted to chief operating officer and head of the PEGylation business unit, while Michael Simms replaces Truc Le as senior vice president of operations.
Anesiva announced two new appointments: Yvonne Richardson as vice president of manufacturing and Shaun Comfort as director of clinical research.
Meanwhile, Robert Haggerty has been appointed to the newly created position of vice president of quality at Hyaluron Contract Manufacturing , a leader in aseptic formulation and filling of liquid parenterals and other medical devices.